Automated Breast Ultrasound Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The ABUS market encompasses automated ultrasound systems, software, accessories, and services designed to provide standardized, reproducible breast imaging as a complement to mammography. Global market size estimates differ by scope: narrow ABUS-system figures are reported near USD 750 million in 2025, while broader assessments that include adjacent ultrasound and breast imaging solutions reach multi-billion-dollar valuations. The market serves hospitals, diagnostic imaging centers, breast clinics, and increasingly outpatient screening programs.

• •Narrow ABUS-system market estimated at about USD 750 million in 2025, with broader breast-imaging assessments reaching multi-billion-dollar levels.
• •Primary use case is supplemental screening for women with dense breast tissue, where mammography sensitivity is reduced.
• •Core product categories include ABUS systems, software, transducers, and service contracts.

Rising global breast cancer incidence and the push for earlier detection are the central demand drivers, alongside growing clinical recognition of dense-breast limitations. Regulatory approvals and expanding reimbursement coverage, particularly in the United States, are accelerating clinical adoption. Technology improvements such as shorter scan times, AI-assisted reading, and better integration with mammography and PACS workflows are also reducing operational barriers.

• •Increasing breast cancer incidence and earlier-detection screening guidelines are expanding the eligible patient population.
• •U.S. FDA clearance and state-level dense-breast notification laws are supporting supplemental screening adoption.
• •AI-based image analysis and workflow integration are shortening reading times and improving throughput.

The market is segmented by product (systems, software, accessories, services), technology (2D and 3D/hybrid), application (screening vs. diagnostic adjunct), and end user (hospitals, imaging centers, breast clinics). North America leads revenue share, driven by established screening infrastructure, reimbursement, and dense-breast legislation, while Europe represents a mature but slower-growing region. Asia-Pacific is the fastest-growing region, supported by expanding healthcare capacity, rising cancer awareness, and growing private diagnostic networks.

• •By product, ABUS systems account for the largest share; software and services are growing fastest as installed bases expand.
• •North America holds the leading share; Asia-Pacific is the fastest-growing regional market.
• •Hospitals are the largest end-user segment, with diagnostic imaging centers gaining share in outpatient screening.

What are the recent trends and outlook?

The near-term outlook is shaped by deeper integration of ABUS with mammography-based screening programs and the rise of bundled 'multimodality' breast imaging workflows. AI-assisted lesion detection and risk-prediction tools are expected to be a key value-add, supporting faster reads and higher reader agreement. With a projected CAGR near 8.4%, the market is likely to see expanding adoption in Asia-Pacific and gradual uptake in Latin America and the Middle East as screening infrastructure matures.

• •AI-driven detection, triage, and risk-modeling tools are the most visible near-term technology trend.
• •Multimodality screening combining mammography, ABUS, and possibly contrast-enhanced imaging is gaining traction.
• •Long-term growth is expected to be strongest in Asia-Pacific, with mature markets focusing on replacing older installed systems.